Having COPD and emphysema not only takes away from quality of life, but also puts individuals at a greater risk of early death from cardiovascular disease.
Salt Lake City, UT (PRWEB) August 31, 2012
With chronic obstructive pulmonary disease (COPD) the third leading cause of death in the United States, Optimum Clinical Research is currently examining a combination of medications that will hopefully prolong life spans while improving breathing functions.
“Having COPD and emphysema not only takes away from quality of life, but also puts individuals at a greater risk of early death from cardiovascular disease,” said Jared Shields, recruitment coordinator at Optimum Clinical Research. “One of the major benefits coming from our latest study is it will give patients access to rare medical testing that isn’t available in many places.”
The Pulse Wave Velocity Testing that will be done as part of the study will let patients see where their blood pressure is at not only in their arm, but also in their heart. Patients will be able to see how hardened arteries have affected their vascular system.
“Hopefully, as they continue with the study they will be able to see an improvement in their vascular system with the combination of medications. The Pulse Wave Velocity Testing will give patients additional knowledge in how well the medication is working for them,” Shields said.
Optimum Clinical Research is currently seeking patients to participate in the COPD/Emphysema study. Visit ocresearch.com to learn more about this and other clinical studies currently being conducted at the clinic.
“Two already-approved COPD medications are being used for the research. The hope is that these two medications will reduce the hardness of arteries, reducing the risk of heart attack and stroke,” Shields explained.
Eligible participants for the COPD/emphysema study must meet the following qualifications:
- Be between the ages of 40 and 80 years old
- Have been diagnosed with COPD, emphysema or chronic bronchitis
- Current or previous smoker
- Have qualifying cardiovascular risk factors that might include coronary artery disease, peripheral vascular disease, stroke, heart attack, diabetes, high cholesterol or high blood pressure.
The benefits of participating in the clinical study include a $50 payment per visit and all study medications are provided. Physical exams and lab tests including pulmonary function tests are also included. There is no cost to participate and insurance is not needed. Participation in the study is on a completely voluntary basis. There is no obligation to continue participating.
For more information about participating in the study, visit http://www.ocresearch.com/copd-or-emphysema/ or call 801-363-7353.
“There are over 13 million American adults suffering from COPD. Shortness of breath, wheezing, irregular breathing, severe coughing, chest tightness, weight loss and swollen legs and ankles are among the symptoms that those with COPD and emphysema face each day,” Shields said. “Our goal is to help relieve symptoms, prevent and treat complications and help slow the progress of the disease.”